Info

Important: Both MadeMed and MEDVi facilitate access to compounded prescription medications that are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This comparison is for educational purposes only. Consult a licensed healthcare provider before starting any prescription treatment. Pricing is subject to change — verify current terms directly on each platform's official website before enrolling.

If you've been researching compounded GLP-1 telehealth programs, you've almost certainly encountered both MadeMed and MEDVi. They're two of the more visible platforms in the current market, they offer overlapping medication formats, and they're both frequently appearing in the same search results. What they don't offer is a side-by-side comparison written by someone who has actually read both platforms' terms, sourced verified pricing, and documented the meaningful differences. That's what this article does.

Company Overview: What Each Platform Is

MadeMed is operated by IDL Health LLC, headquartered in Houston, Texas. Medical services are provided by Xpedicare, LLC, an independent medical group whose licensed clinicians make all prescribing decisions. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner. MadeMed holds LegitScript certification. As of available verified sources, no FDA warning letters have been identified for MadeMed as of the date of this review.

MEDVi is a telehealth platform that has been operating since 2023 and is based in Newark, Delaware. Prescriptions are overseen by board-certified U.S. physicians through the OpenLoop Health provider network. Medication is dispensed through Belmar Pharma Solutions, a licensed compounding pharmacy operating since 1985 and accredited by NABP across all its locations. MEDVi holds LegitScript certification and reports serving over 100,000 patients. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language the FDA found implied FDA approval and suggested MEDVi was the compounder of the medications it sold. The letter did not allege contaminated or improperly manufactured medications. For our full independent review of MEDVi's platform, see our MEDVi GLP-1 program review.

Verified Pricing Comparison: What Each Platform Actually Charges

The pricing figures below are drawn from publicly available sources verified as of April to May 2026. All prices represent published starting doses. Dose increases typically increase cost. Verify current pricing directly on each platform before enrolling.

Injectable Semaglutide: MadeMed lists $179 per month at the starting dose (0.25mg), inclusive of L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) reduces this by $10 per month. MEDVi lists $179 for the first month as an introductory rate, then $299 per month for ongoing refills. MEDVi charges no separate membership fee.

Oral Semaglutide (sublingual): MadeMed lists $169 per month at the starting dose (1mg), with 30 sublingual tablets. MadeMed Club reduces this by $10 per month. MEDVi lists oral semaglutide tablets starting at $249 for the first month, then $369 per month ongoing. At every dose tier in available verified data, MadeMed's published oral semaglutide price is lower than MEDVi's.

Injectable Tirzepatide: MadeMed lists $189 per month at the starting dose (2.5mg), inclusive of the same supplies package as semaglutide. MadeMed Club reduces this by $20 per month. MEDVi lists injectable tirzepatide starting at $279 for the first month, then $399 per month ongoing.

Oral Tirzepatide (sublingual): Neither platform has a confirmed published starting price for oral tirzepatide in independently verified sources as of this writing. MEDVi's ongoing rate for compounded tirzepatide (injectable and oral combined into one tier) is reported at $399 per month. Verify oral tirzepatide pricing and current availability directly on each platform. Note: as of January 2026, there is no FDA-approved oral tirzepatide product in any format. Oral tirzepatide from telehealth platforms is a compounded sublingual formulation that has not been evaluated by the FDA.

One structural pricing difference worth understanding: MEDVi bills on a 28-day cycle rather than a calendar month, producing 13 billing events per year rather than 12. At $299 per month for semaglutide, the annual cost is approximately $3,887 — not $3,588 as a 12-month calculation would suggest. MadeMed's billing cycle structure (30-day vs. 90-day subscription options) should be verified directly on the platform.

What's Included: The Bundling Difference

MadeMed explicitly states that its injectable programs include L-Carnitine, physician consultation, overnight shipping, and injection supplies in the listed monthly price. For patients who would otherwise pay separately for these items, the all-in pricing model simplifies cost comparison. MEDVi's pricing includes provider consultation and medication; verify current shipping and supply terms directly on MEDVi's platform, as bundling structures in the telehealth market can change.

The MadeMed Club membership ($149/year) provides monthly discounts of $10 on semaglutide programs and $20 on tirzepatide programs. At the tirzepatide discount rate, the membership pays for itself in approximately 7.5 months. For patients planning a sustained treatment course, the math favors joining. For patients uncertain about long-term commitment, the month-to-month standard pricing avoids the upfront membership cost.

Medication Range: Where the Platforms Diverge

For GLP-1 programs specifically, both platforms offer the same four core formats: injectable semaglutide, oral sublingual semaglutide, injectable tirzepatide, and oral sublingual tirzepatide. MEDVi additionally offers access to brand-name Wegovy and Ozempic at premium pricing tiers for patients who specifically require FDA-approved finished drug products — an option MadeMed does not appear to offer, according to available verified sources.

MadeMed's range extends beyond GLP-1 into categories MEDVi doesn't cover: sermorelin-based peptide therapy in injectable and oral formats, a tadalafil/PT-141/oxytocin men's wellness troche, and NAD+ therapy in injectable and nasal spray formats. For patients whose clinical needs include any of these categories, in addition to weight management, MadeMed offers a single-platform model that MEDVi doesn't match. For our detailed breakdown of MadeMed's peptide and NAD+ programs, see our MadeMed sermorelin and peptide therapy review.

Regulatory History: What the Record Shows

This section matters more in 2026 than it would have in prior years, given the FDA's escalated enforcement posture in the compounded GLP-1 market since September 2025.

MEDVi received a formal FDA warning letter in February 2026. The letter cited misbranding violations specifically — marketing language the agency found implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. MEDVi holds active LegitScript certification as of the publication date of this review, and the warning letter did not allege medication contamination or manufacturing deficiencies. Warning letters require a response and corrective action; they do not automatically result in enforcement action or platform shutdown. But they are on the public record, and patients evaluating platforms should know they exist.

No FDA warning letters have been identified for MadeMed in available verified sources as of this writing. This is not a guarantee of future regulatory status — the compounded GLP-1 market remains under active FDA scrutiny, and conditions for all platforms in this space continue to evolve.

Patient Review Volume and Signals

MEDVi has a substantially larger public review footprint: over 10,000 Trustpilot reviews with a 4.4 to 4.5 star average as of early 2026. Common praise focuses on fast approval, clinical team responsiveness, and accessible provider messaging. Common complaints cluster around billing practices and subscription management — a pattern typical of telehealth platforms using auto-renewal subscription models, not a signal specific to clinical quality.

MadeMed has a smaller public review volume, consistent with its relative market age. A smaller review footprint does not indicate lower quality — it reflects how recently a platform entered the market and how aggressively it has solicited public reviews. Evaluate review signals as one data point among several, not as a primary decision factor.

State Availability

MEDVi reports availability in 49 states (North Dakota excluded as of early 2026 data). MadeMed reports availability in approximately 40 states. If your state's availability is a deciding factor, verify both platforms' current service areas directly — state-level availability in the telehealth GLP-1 market changes as platforms adjust to evolving state telehealth regulations.

How to Choose Between Them

If your primary goal is compounded GLP-1 for weight management and you want the lowest published starting price across semaglutide formats, MadeMed's published pricing is lower at every tier in the verified data. If you want access to brand-name FDA-approved GLP-1 options through the same platform, MEDVi offers that and MadeMed does not appear to. If you need peptide therapy or NAD+ alongside a GLP-1 program, MadeMed is the single-platform option. If you want the largest available patient review base as a signal before committing, MEDVi's review volume is substantially larger. If FDA warning letter history factors into your evaluation, MEDVi has one on record from February 2026 and MadeMed does not.

Neither of these is a definitive answer about which platform is better for any individual patient. The right platform is the one whose clinical team, after reviewing your specific health history, determines an appropriate treatment path for you. Both platforms use licensed clinicians for that determination. Both use licensed pharmacy partners for dispensing. Both operate under the same compounded medication regulatory framework. The differences are in pricing structure, medication range, regulatory history, and review volume — all of which are factors you can evaluate before completing an intake form. For our full breakdowns, see the complete MadeMed review and the complete MEDVi review.

Frequently Asked Questions

Is MadeMed or MEDVi cheaper for injectable semaglutide?

Based on published April 2026 pricing, MadeMed lists injectable semaglutide at $179 per month — identical to MEDVi's introductory first-month rate. MEDVi's ongoing monthly rate after the first month rises to $299. MadeMed's published pricing does not clearly distinguish between an introductory and an ongoing rate in the available verified sources; verify current tier pricing directly on each platform before enrolling.

Did MEDVi receive an FDA warning letter?

Yes. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language that implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. The letter did not allege that the medications were contaminated or improperly manufactured. MEDVi holds an active LegitScript certification as of the publication date of this review.

Which platform offers more medication formats?

Both platforms offer compounded semaglutide and tirzepatide in injectable and sublingual oral formats. MadeMed additionally offers sermorelin peptide therapy (injectable and oral) and NAD+ therapy (injectable and nasal spray). MEDVi offers brand-name Wegovy and Ozempic at premium pricing tiers. The right platform depends on which medications and categories are relevant to your individual situation.

Which platform has more patient reviews?

MEDVi has a substantially larger public review footprint, with over 10,000 Trustpilot reviews and an average rating of 4.4 to 4.5 as of early 2026. MEDVi has been operating since 2023 and reports serving over 100,000 patients. MadeMed has a smaller public review volume reflecting its relative market age. Review volume and scores are useful signals, but should not be the sole basis for a prescribing decision.

Important: Sermorelin and other peptide therapies discussed in this article are prescription medications. Compounded formulations are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational purposes only. Consult your licensed healthcare provider before starting any prescription peptide therapy.

Most coverage of MadeMed focuses on its GLP-1 weight-loss programs, which makes sense — that's where patient volume and search interest are highest. But MadeMed also offers sermorelin-based peptide therapy in both injectable and oral formats, and that category deserves the same research-depth treatment this site applies to every telehealth program we review. This article covers what sermorelin is, what the clinical evidence actually supports, how MadeMed's peptide programs are structured, and the regulatory context you need to understand before enrolling.

What Is Sermorelin?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone, or GHRH. Rather than introducing exogenous growth hormone directly — as growth hormone replacement therapy does — sermorelin stimulates the pituitary gland to produce and release growth hormone via the body's natural regulatory feedback mechanisms. This distinction matters clinically. Because sermorelin operates upstream of growth hormone production rather than bypassing the regulatory system entirely, it preserves the pituitary's own feedback controls to a greater degree than direct growth hormone administration.

Sermorelin was previously FDA-approved under the name Geref for the evaluation and treatment of growth hormone deficiency in children. That approval was voluntarily withdrawn by the manufacturer — not due to a safety finding, but for commercial reasons. Sermorelin prescribed through telehealth platforms today is compounded, meaning it is formulated by a licensed compounding pharmacy for specific patients and is not an FDA-approved finished drug product.

What the Research Supports — and What It Doesn't

The evidence base for sermorelin is meaningful but narrower than its marketing footprint might suggest. Published research has examined sermorelin's effects on growth hormone secretion, IGF-1 levels, body composition, and sleep quality in specific populations, primarily adults with documented growth hormone deficiency or age-related growth hormone decline. Studies have shown that sermorelin can stimulate measurable increases in growth hormone output in appropriate patient populations when administered via injection. The clinical rationale for its use exists.

What the research does not support: sermorelin as a general anti-aging treatment, as a performance enhancement tool for individuals with normal growth hormone levels, or as a guaranteed approach to improving body composition or energy in non-deficient adults. Sermorelin is not approved for these applications. No legitimate medical provider can guarantee outcomes from peptide therapy, and claims that sermorelin will produce specific effects on body composition, energy, or longevity in unselected patient populations exceed what peer-reviewed evidence supports.

The more difficult research question applies specifically to oral sermorelin. Peptides face significant challenges with oral bioavailability. The gastrointestinal tract contains proteases that degrade peptides before they reach systemic circulation, which is why most established peptide therapies use injectable delivery routes. The clinical evidence base for oral sermorelin formulations — including any sublingual or swallowed tablet format — is substantially more limited than for injectable sermorelin. This is not unique to MadeMed; it applies to oral peptide delivery across the telehealth market.

How MadeMed's Peptide Therapy Programs Are Structured

MadeMed offers sermorelin in both injectable and oral formats. The enrollment process follows the same telehealth model as the platform's GLP-1 programs: prospective patients complete an online medical intake, which is reviewed by a licensed clinician affiliated with Xpedicare, LLC. Prescribing is at the clinician's sole discretion. There is no guarantee that a prescription will be issued. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner, and shipped directly to the patient.

Sermorelin is typically administered at night, before sleep, because growth hormone secretion follows a circadian pattern with peak release during slow-wave sleep. Injectable sermorelin is administered subcutaneously — the same delivery method as injectable GLP-1 medications. Dosing and titration protocols are determined by the prescribing clinician based on individual patient assessment.

The subscription and billing structure for peptide therapy follows the same terms as MadeMed's other programs: recurring billing (30 or 90 day cycles), no prorated refunds, cancellation available via email or through the patient portal. Review the full Terms of Use at mademed.com before enrolling.

NAD+ Therapy: MadeMed's Other Longevity Category

MadeMed also offers NAD+ (nicotinamide adenine dinucleotide) therapy in injectable and nasal spray formats, priced up to $269 per month for the nasal spray at higher tiers. NAD+ is a coenzyme involved in cellular energy metabolism, and there is ongoing research interest in NAD+ precursors and direct NAD+ supplementation in the context of aging and metabolic health. As with sermorelin, the clinical evidence base for NAD+ therapy in healthy, non-deficient adults — and specifically for injectable and nasal spray formats at the doses used in telehealth programs — is substantially more limited than the marketing language around “longevity medicine” typically conveys. Discuss the evidence with your provider before starting any NAD+ program.

Who Peptide Therapy May Be Appropriate For

Sermorelin may be clinically appropriate for adults with documented growth hormone deficiency confirmed through lab testing, or for individuals where a licensed clinician determines it may be medically indicated after reviewing individual health history and goals. It is not a general wellness product and is not appropriate as a self-directed supplement or as a substitute for lifestyle interventions in growth-hormone-sufficient adults. Clinical evaluation before prescribing — including a thorough health history review — is the baseline standard for any responsible peptide therapy program.

If you're researching MadeMed primarily for weight loss support, the GLP-1 programs are the more evidence-anchored starting point. See our full MadeMed platform review for a complete breakdown of all programs, pricing, and what to verify before enrolling. For comparison with other telehealth platforms that offer peptide therapy alongside GLP-1 programs, see our review of TeleHealth Med, which covers a comparable care model.

What to Ask Your Provider Before Starting Sermorelin

Has your growth hormone status been evaluated through lab testing? What IGF-1 levels would indicate you're a candidate for sermorelin therapy? Will you receive a baseline lab assessment before prescribing? What does dose titration look like and how is response monitored over time? What is the compounding pharmacy's accreditation status and quality assurance process for the specific formulation? How long is a reasonable trial period before evaluating whether the therapy is producing any measurable response? Are there contraindications given your current medications or health history?

These are not difficult questions — they're the baseline clinical due diligence any responsible provider should be prepared to answer. A platform or provider that can't or won't engage with them is a signal to seek a different clinical relationship.

Frequently Asked Questions

What is sermorelin and how does it work?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release growth hormone through the body's natural regulatory pathways, rather than introducing exogenous growth hormone directly. It requires a licensed provider evaluation and is not approved for anti-aging or general wellness use. Clinical applications have included evaluation for growth hormone deficiency under physician supervision.

Is MadeMed's sermorelin FDA-approved?

Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency, but that approval was voluntarily withdrawn by the manufacturer. Sermorelin prescribed through telehealth platforms today is typically compounded, meaning it is not an FDA-approved finished drug product and has not been evaluated by the FDA for safety or efficacy in its compounded form.

What is the difference between injectable and oral sermorelin at MadeMed?

MadeMed offers both injectable and oral sermorelin formats. Injectable sermorelin is administered subcutaneously and is the more established delivery route in clinical literature. Oral peptide delivery faces significant bioavailability challenges due to degradation in the gastrointestinal tract. The clinical evidence base for oral sermorelin formulations is substantially more limited than for injectable formats. Discuss which format is appropriate for your situation with a licensed provider before starting.

Important: Compounded GLP-1 medications discussed in this article are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational and informational purposes only. All prescription decisions are made by licensed healthcare providers. Consult your provider before starting any prescription medication.

One of the most common questions prospective patients ask about GLP-1 telehealth programs right now is whether the oral format actually works — and whether it's worth choosing over an injectable. MadeMed offers both, starting at $99 per month for oral semaglutide and also offering injectable semaglutide and both oral and injectable tirzepatide. This article breaks down what the research actually supports, what “oral semaglutide” means in the telehealth context, and how to think about the format decision from an evidence standpoint.

What “Oral Semaglutide” Actually Means in 2026

The term “oral GLP-1” covers at least four meaningfully different things in the current market, and conflating them produces bad decisions. Understanding the distinctions is the most important thing this article can offer.

FDA-approved oral semaglutide includes two products: Rybelsus, a daily swallowed tablet approved for type 2 diabetes management, and the oral Wegovy formulation that launched in late 2025 for weight management. Both have completed phase 3 clinical trial programs evaluating their efficacy, safety, and pharmacokinetics as finished drug products. They require specific administration conditions — typically an empty stomach, small amount of water, and a waiting period before eating — because oral bioavailability of semaglutide is inherently challenging due to its peptide structure and susceptibility to gastric degradation.

Compounded sublingual semaglutide — the format available through MadeMed and most other GLP-1 telehealth platforms — is a separate category. These are compounding pharmacy formulations that dissolve under the tongue rather than being swallowed. The mechanism bypasses initial gastric transit by relying on sublingual absorption through the mucous membranes. This is a pharmacologically coherent delivery route. However, compounded sublingual semaglutide has not been evaluated in equivalent phase 3 human clinical trials. The bioavailability, pharmacokinetic profile, and clinical outcomes of these formulations cannot be assumed to match those of either FDA-approved injectable semaglutide or FDA-approved oral semaglutide based on preclinical or theoretical arguments alone.

This isn't a reason to dismiss the format — it's a reason to understand what you're actually choosing. For a detailed review of how MadeMed structures its programs across all GLP-1 formats, see our full MadeMed platform review.

What the Injectable Evidence Base Establishes

Injectable semaglutide has the strongest and most established evidence base of any semaglutide formulation. The STEP trial program, published in peer-reviewed literature including the New England Journal of Medicine, studied once-weekly subcutaneous semaglutide at 2.4mg in adults with obesity combined with lifestyle intervention. The STEP 1 trial found clinically meaningful average body weight reduction in the treatment group versus placebo after 68 weeks. These are the trials that established the clinical rationale for GLP-1 therapy in weight management — and they used injectable, FDA-approved branded semaglutide under controlled trial conditions.

Compounded injectable semaglutide — the format also available through MadeMed — uses the same active ingredient (semaglutide) administered the same way (subcutaneous injection), but is a compounded formulation rather than an FDA-approved finished drug. The pharmacological mechanism is the same, but the regulatory status, quality control standards, and evidence basis for the specific compounded formulation differ. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality control before they are dispensed.

The Oral Semaglutide Clinical Picture: What Phase 3 Data Shows for FDA-Approved Formats

The oral Wegovy clinical program (OASIS trials) evaluated swallowed oral semaglutide at 50mg once daily in adults with obesity. Published results demonstrated meaningful weight reduction compared to placebo, though average weight loss figures were somewhat lower than those observed in the injectable STEP trials. These results establish proof of concept for oral semaglutide as a clinically effective approach — but again, these are trials of an FDA-approved finished drug product, not of compounded sublingual tablets.

The mechanistic argument for sublingual absorption is that it bypasses the gastric degradation challenge that makes oral peptide delivery difficult. Whether compounded sublingual semaglutide achieves clinically meaningful systemic exposure in practice — and at what doses — is not established by published phase 3 human trial data as of this writing. This is a genuine evidence gap, not a disqualifying flaw. Clinicians prescribe medications through compounding when the individual patient's needs support it. But patients deserve to know that the “oral semaglutide” available through telehealth platforms is not the same product, and does not have the same evidence base, as the oral Wegovy pill that launched in late 2025.

How MadeMed's Oral Semaglutide Pricing Compares to the Market

At a published starting price of $99 per month, MadeMed's oral semaglutide sits at the lower end of the compounded telehealth market for this format. For context, oral semaglutide sublingual tablets from other platforms are priced higher: the SynergyRx oral dissolving tablet program starts at $299 per month for semaglutide per publicly available information, while programs reviewed on this site, including FuturHealth and Remote Pharmacy, structure their pricing differently, with injectable-focused programs in comparable ranges.

The key pricing consideration that every prospective patient should apply: compare total cost at maintenance dose, not starting price. GLP-1 programs titrate upward over months. The $99 entry point applies to the lowest starting dose of oral semaglutide — the dose at which most clinical protocols begin before gradually increasing. As dose increases, price increases. The monthly cost at a therapeutic maintenance dose will be higher than the published starting price. Verify the full pricing tier structure directly on mademed.com before enrolling.

For the FDA-approved oral alternative: Novo Nordisk has published self-pay pricing for oral Wegovy at $149 per month for certain dose tiers through its manufacturer direct program. For patients who qualify and prefer an FDA-approved finished drug, the price differential between compounded sublingual semaglutide and the approved oral pill has narrowed significantly in 2026. This is a conversation to have with your prescribing clinician — not a decision to make based on cost alone, since eligibility, insurance, and individual medical history all factor in.

How to Think About the Format Decision

The right format — oral or injectable — is a clinical decision, not a marketing decision. A few questions worth discussing with your provider: Do you have any medical reason to avoid subcutaneous injections? Does your state's prescribing regulations or the platform's clinical protocols affect which formats are available to you? Is there a compounded tirzepatide option worth considering if semaglutide isn't the right fit? Are you looking for an FDA-approved finished drug product specifically, or are you open to a compounded formulation under medical supervision?

MadeMed offers the flexibility of both formats across two GLP-1 molecules (semaglutide and tirzepatide), which is a genuine differentiator compared to platforms that offer only one format or one molecule. Whether that flexibility translates to better outcomes for any individual patient is a question for their licensed clinician.

Frequently Asked Questions

Is oral semaglutide as effective as injectable semaglutide?

FDA-approved oral semaglutide (Rybelsus and oral Wegovy) has been studied in clinical trials and demonstrates meaningful weight reduction, though phase 3 trial data generally shows somewhat less average weight loss compared to injectable semaglutide at equivalent doses. Compounded sublingual semaglutide tablets — the format available through most telehealth platforms — have not been evaluated in equivalent phase 3 human trials. The bioavailability and clinical outcomes of compounded sublingual formats cannot be assumed to be equivalent to either FDA-approved injectable or FDA-approved oral semaglutide products.

Why is MadeMed's oral semaglutide priced lower than competitors?

MadeMed's published starting price for oral semaglutide ($99/month at the lowest dose) positions it at the lower end of the compounded telehealth market. Pricing differences between telehealth platforms reflect differences in pharmacy sourcing, bundled services, dose tier structures, and membership models. Lower starting price does not always reflect lower total cost at maintenance dose. Prospective patients should compare total monthly cost at their expected therapeutic dose, not just entry-level pricing.

What is the difference between compounded sublingual semaglutide and oral Wegovy?

Oral Wegovy is an FDA-approved finished drug product that has completed phase 3 clinical trials evaluating its safety, efficacy, and bioavailability as a swallowed tablet. Compounded sublingual semaglutide — the format available through telehealth platforms including MadeMed — is a compounding pharmacy formulation that dissolves under the tongue. It uses semaglutide as an active ingredient but is not FDA-approved and has not been evaluated in equivalent human clinical trials. The two formats have different regulatory statuses and different evidence bases.

Important: MadeMed is a telehealth platform that facilitates access to prescription medications. It does not provide direct medical care. All prescribing decisions are made by licensed clinicians affiliated with Xpedicare, LLC, an independent medical group. Compounded medications dispensed through this platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This review is for informational and educational purposes only. Consult your healthcare provider before starting any prescription treatment.

The compounded GLP-1 telehealth market has expanded to dozens of platforms in the last two years, and most of what you'll find when you search for reviews falls into one of two failure modes: promotional content that reads like a sales page, or vague skepticism that doesn't tell you anything specific. This review does neither. We examined MadeMed's public-facing website, its Terms of Use, third-party verification sources, and the broader regulatory environment around compounded semaglutide to give you a research-level breakdown of what this platform actually offers — and what you need to verify before enrolling.

What Is MadeMed?

MadeMed is an online telehealth platform operated by IDL Health LLC, headquartered in Houston, Texas. The platform connects patients with licensed medical providers affiliated with Xpedicare, LLC, an independent medical group that is solely responsible for clinical services and all prescribing decisions. MadeMed holds LegitScript certification, an independent verification standard that evaluates online healthcare companies for legal compliance, safety, and transparency. Medication is dispensed through AbsoluteRx, a licensed pharmacy partner.

The platform operates across four clinical categories: GLP-1 weight loss programs, men's sexual health, peptide therapy, and NAD+ therapy. For most prospective patients, the GLP-1 weight-loss programs are the primary focus—and that's where the majority of this review is concentrated.

MadeMed GLP-1 Programs: What the Platform Offers

MadeMed offers four GLP-1 medication formats. Injectable semaglutide and injectable tirzepatide are the traditional subcutaneous injection options administered once weekly. Oral semaglutide and oral tirzepatide are compounded sublingual tablet formulations that dissolve under the tongue — a needle-free alternative that has grown significantly in market share among telehealth GLP-1 platforms in 2025 and 2026.

It's worth being specific about what “oral semaglutide” means in this context. The compounded sublingual tablets available through MadeMed and most telehealth platforms differ from the FDA-approved oral semaglutide products that have reached the market — specifically Rybelsus (the original oral tablet) and the oral Wegovy formulation launched in late 2025. Compounded sublingual semaglutide is not an FDA-approved finished drug and has not been evaluated in phase 3 human trials for efficacy or bioavailability under the same conditions as the approved oral formulations. For a more detailed breakdown of the oral format landscape, see our comparison of oral GLP-1 telehealth programs.

MadeMed Pricing: What the Published Numbers Actually Mean

Based on publicly available information as of May 2026, MadeMed's oral semaglutide program starts at $99 per month at the lowest dose tier. Pricing increases as doses are titrated upward throughout treatment. NAD+ nasal spray is listed at up to $269 per month at higher tiers. An optional MadeMed Club membership, priced at $149 per year, provides a $10 monthly discount across the platform's programs.

A few pricing realities worth understanding before you commit. First, the starting price is almost never the price you'll actually pay at a therapeutic maintenance dose. GLP-1 programs begin at the lowest titration dose — typically 0.25mg for semaglutide — and increase over months based on individual response and tolerability. The per-month cost typically increases with dose. Second, subscription billing is automatic. MadeMed's Terms of Use state that services are offered on a recurring subscription basis and that the platform does not offer prorated refunds. Cancellation is available via email to support@mademed.com or through the account portal and takes effect at the end of the current billing period. Read those terms before you enter payment information.

For context on how MadeMed's pricing compares to other compounded GLP-1 platforms in the current market, see our analysis of the MEDVi GLP-1 program, which starts at $179 per month for injectable semaglutide, and our review of SynergyRx GLP-1, which offers oral dissolving tablet options starting at $299 per month for semaglutide. At its published starting price, MadeMed's oral semaglutide option sits at the lower end of the compounded telehealth market.

Regulatory Context: Compounded Medications and the 2025-2026 Enforcement Environment

This section matters more in 2026 than it would have two years ago, and anyone considering a compounded GLP-1 program should understand it clearly.

Compounded medications are patient-specific formulations prepared by licensed compounding pharmacies. They are legal and widely prescribed, but they are not FDA-approved finished drugs. The FDA does not evaluate compounded medications for safety, efficacy, or quality control before they are dispensed. MadeMed's Terms of Use state this explicitly: “Compounded drugs are not approved by the Food and Drug Administration (FDA) and are not evaluated for safety or efficacy.” That level of disclosure is legally required and factually accurate.

The broader regulatory environment has shifted since mid-2025. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024. When a branded drug is no longer on the FDA shortage list, the legal authority for compounding pharmacies to produce bulk copies of that drug significantly narrows. The FDA has escalated enforcement against compounded GLP-1 marketing since September 2025, issuing warning letters to multiple telehealth platforms for misbranding violations. In March 2026, Hims & Hers reached a settlement with Novo Nordisk and announced it would stop marketing compounded GLP-1 medications, signaling a major pivot among large-scale telehealth players.

None of this means compounded semaglutide or tirzepatide is currently unavailable or illegal. Patient-specific compounding through 503A pharmacies remains a legal pathway when a prescribing clinician determines a compounded formulation is medically necessary for a specific patient. But the landscape is actively changing, and platforms operating in this space — including MadeMed — face ongoing regulatory scrutiny. Prospective patients should verify current program availability, pricing, and medication sourcing directly on mademed.com before enrolling, as conditions may have changed since this review was written.

The Weight Loss Outcome Claim: What the Research Actually Supports

MadeMed cites an average body weight loss of 15 to 20 percent on its platform. This figure deserves precise context. The 15 to 20 percent body weight reduction range reflects outcomes reported in large-scale clinical trials of FDA-approved semaglutide at the 2.4mg weekly dose — specifically the STEP trial program, which studied brand-name injectable Wegovy in adults with obesity alongside lifestyle intervention. Those trials involved FDA-approved finished drug formulations, conducted in controlled conditions, and enrolled populations meeting specific eligibility criteria.

That clinical literature does not establish that MadeMed's compounded semaglutide products — which are not FDA-approved and have not been evaluated in equivalent trials — will produce the same outcomes. Individual weight-loss results depend on dose, adherence, individual physiology, lifestyle factors, starting weight, and other variables. No telehealth platform can guarantee specific outcomes from compounded GLP-1 therapy, and none should. The research supports that semaglutide, when prescribed appropriately and used alongside lifestyle modification under medical supervision, has demonstrated meaningful weight reduction in certain patient populations. Whether any individual qualifies for and responds to GLP-1 therapy is a clinical determination — one made by the licensed providers within Xpedicare, LLC, not by MadeMed.

The MadeMed Intake and Prescribing Process

The enrollment process follows the standard telehealth model used across the compounded GLP-1 market. Prospective patients complete an online medical intake form covering health history, current medications, and weight goals. That information is reviewed by a licensed clinician affiliated with Xpedicare, LLC. The Terms of Use make clear that there is no guarantee a prescription will be written — the prescribing decision is entirely at the clinician's discretion based on their professional judgment. MadeMed's Terms of Use also specify that providers do not prescribe DEA-controlled substances.

If a prescription is issued, it is transmitted to AbsoluteRx, MadeMed's licensed pharmacy partner, for fulfillment and direct shipment. Services run on a subscription billing cycle — either 30 or 90 days, depending on the plan selected.

MadeMed's Other Programs: Men's Health, Peptide Therapy, and NAD+

Beyond GLP-1, MadeMed offers a tadalafil-based men's sexual health troche that combines tadalafil with PT-141 and oxytocin. For peptide therapy, the platform offers both injectable and oral sermorelin. Sermorelin is a peptide that may support growth hormone release in certain individuals under medical supervision; it is not approved for anti-aging or general wellness use and requires appropriate clinical evaluation before prescribing. NAD+ therapy is available as both an injectable and a nasal spray.

For a focused review of MadeMed's sermorelin and peptide therapy programs specifically, see our dedicated breakdown: MadeMed Sermorelin and Peptide Therapy: What Patients Should Know.

Is MadeMed Legitimate? What Independent Verification Tells Us

Based on available information: yes, MadeMed is a real, operating telehealth platform. LegitScript certification indicates the platform has met independent standards for legal compliance and safety in online healthcare operations. The three-entity structure — MadeMed as the platform operator, Xpedicare, LLC as the independent medical group providing clinical services, and AbsoluteRx as the pharmacy partner — is consistent with how compliant telehealth platforms structure the separation between non-clinical services and medical care.

The more useful question for prospective patients is not “is it legitimate?” but “is it the right fit for me?” That depends on your state's availability, your medical history, whether compounded GLP-1 therapy is appropriate for your specific situation, the current regulatory status of the programs you're considering, and how MadeMed's pricing compares at your expected maintenance dose. The answer to those questions requires a conversation with a licensed clinician — one who has reviewed your actual health history. For additional context on how MadeMed compares to other platforms with similar care models, see our reviews of Direct Meds GLP-1 and TeleHealth Med.

What to Verify Before Enrolling with MadeMed

Confirm your state is included in MadeMed's current service area — approximately 40 states as of this writing, but subject to change. Verify current pricing for the specific medication and dose tier you're likely to reach at maintenance, not just the starter price. Read the subscription and cancellation terms in MadeMed's Terms of Use before entering payment information. Ask your prescribing clinician about the pharmacy sourcing for your specific formulation and request a Certificate of Analysis if you want to verify medication quality and ingredient testing. If you are currently taking any medications, including thyroid medications or GLP-1 pathway medications, discuss potential contraindications with a qualified provider before starting. And verify current program availability and pricing directly on mademed.com, as the compounded GLP-1 regulatory environment continues to evolve and information in third-party reviews — including this one — may not reflect the most current program terms.

Frequently Asked Questions

Is MadeMed a legitimate telehealth platform?

MadeMed is operated by IDL Health LLC and holds LegitScript certification. Medical services are provided by Xpedicare, LLC, an independent medical group. All prescribing decisions are made by licensed clinicians — not MadeMed — and medication is dispensed through AbsoluteRx, a licensed pharmacy partner.

How much does MadeMed cost per month?

Published pricing starts at $99 per month for oral semaglutide. NAD+ nasal spray is listed up to $269 per month. An optional MadeMed Club membership at $149 per year provides a $10 monthly discount. Final pricing depends on medication type, dose, and plan structure and should be verified directly on mademed.com before enrollment.

Are MadeMed's GLP-1 medications FDA-approved?

No. MadeMed's Terms of Use state explicitly that compounded medications dispensed through the platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This is the regulatory standard for all compounded drugs in the United States.

What states is MadeMed available in?

MadeMed reports availability in approximately 40 states. Certain medications or clinical services may not be available in all states due to state-specific restrictions. Prospective patients should verify their state's availability directly on the platform before completing an intake form.

What medications does MadeMed offer?

MadeMed offers injectable and oral compounded semaglutide, injectable and oral compounded tirzepatide, a tadalafil-based men's wellness troche, injectable and oral sermorelin for peptide therapy, and NAD+ in both injectable and nasal spray formats.